The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker
Information source: Rambam Health Care Campus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia
Intervention: Niacin\Laropiprant (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: Rambam Health Care Campus Official(s) and/or principal investigator(s):
Liz Phima, Study Director, Affiliation: Study Coordinator
Overall contact:
Shadi Hamoud, Dr, Phone: +972-523591876, Email: s_hamoud@rambam.health.gov.il
Summary
1. Treatment of Hypercholesterolemic patients with niacin will cause a significant
decrease in oxidative stress and a decrease in the atherogenecity in blood samples of
the patients.
2. A possible correlation between oxidative stress in hypercholesterolemic patients taking
niacin to clinical hypercholesterolemia parameters is possible.
3. Using a novel biomarker will enable a precise detection of the change in the oxidative
stress in hypercholesterolemic patients.
Clinical Details
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Effect on oxidative stress
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypercholesterolemia,
- age above eighteen
Exclusion Criteria:
- Treatment with fibrates,
- Pregnant/Breast feeding women
Locations and Contacts
Shadi Hamoud, Dr, Phone: +972-523591876, Email: s_hamoud@rambam.health.gov.il
Rambam Health Care Campus, Haifa 31096, Israel; Not yet recruiting
Shadi, Phone: +972-523591876, Email: s_hamoud@rambam.health.gov.il
Tony Hayek, Prof, Phone: +972-523782009, Email: t_hayek@rambam.health.gov.il
Tony Hayek, Prof, Sub-Investigator
Additional Information
Starting date: April 2010
Last updated: February 25, 2010
|
